AMGN Technical Analysis
AMGN Technical Analysis Data
As of date:10/19/2021
AMGN stock price:206.78
AMGN 50 DMA:217.44
AMGN 200 DMA:233.92
AMGN MACD (200-50):16.48
AMGN RSI:36.78
Extremely
Overbought
Overbought/Oversold RSI Range
RSI Indicator (Relative Strength Index)36.78
Extremely
Oversold

Also see:
AMGN Market Cap History
AMGN Shares Outstanding History
AMGN YTD Return

Try ChartSweeps today
AMGN Current Stock Quote
Quotes delayed 20 minutes

Email EnvelopeFree AMGN Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
AMGN Stock Price Chart
Technical Analysis News

Levi Strauss Breaks Above 200-Day Moving Average - Bullish for LEVI
1 hour, 15 minutes ago


DCUE Makes Bullish Cross Above Critical Moving Average
1 hour, 15 minutes ago


GOOS Makes Bullish Cross Above Critical Moving Average
1 hour, 19 minutes ago


XYF Crosses Above Key Moving Average Level
1 hour, 19 minutes ago


SPR Crosses Above Key Moving Average Level
1 hour, 24 minutes ago


BKU Crosses Above Key Moving Average Level
1 hour, 24 minutes ago


DAQO New Energy Breaks Above 200-Day Moving Average - Bullish for DQ
1 hour, 24 minutes ago


Centene (CNC) Shares Cross Above 200 DMA
1 hour, 32 minutes ago


NGG Makes Bullish Cross Above Critical Moving Average
1 hour, 32 minutes ago


Terex (TEX) Shares Cross Above 200 DMA
1 hour, 39 minutes ago


Bullish Two Hundred Day Moving Average Cross - SRE
1 hour, 39 minutes ago


KMT Crosses Above Key Moving Average Level
1 hour, 47 minutes ago


HTEC Makes Bullish Cross Above Critical Moving Average
1 hour, 47 minutes ago


AVEM Shares Cross Above 200 DMA
1 hour, 47 minutes ago


CMS Energy Shares Cross Above 200 DMA
1 hour, 48 minutes ago


More Technical Analysis News

AMGN Technical Analysis Charts
AMGN Technical AnalysisAMGN RSI
About Amgen Inc
Amgen is a biotechnology company that discovers, develops, manufactures and delivers human therapeutics. Co.'s products include: Enbrel® (etanercept), which is used in indications for the treatment of adult patients with moderately to severely active rheumatoid arthritis, patients with chronic moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy and patients with active psoriatic arthritis; and Prolia® (denosumab), which it is used for the treatment of postmenopausal women with osteoporosis at high risk of fracture or multiple risk factors for fracture; or in patients who have failed or are intolerant to other available osteoporosis therapy.

When researching a stock like Amgen, many investors are the most familiar with Fundamental Analysis — looking at a company's balance sheet, earnings, revenues, and what's happening in that company's underlying business. Investors who use Fundamental Analysis to identify good stocks to buy or sell can also benefit from AMGN Technical Analysis to help find a good entry or exit point. Technical Analysis is blind to the fundamentals and looks only at the trading data for AMGN stock — the real life supply and demand for the stock over time — and examines that data in different ways.
Featured Slideshows
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks
10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
AMGN Technical Analysis Charts
AMGN DMAAMGN MACD
Video: Technical Analysis
Video: Technical Analysis


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
AMGN Technical Analysis Peers
Amgen (AMGN) is categorized under the Healthcare sector; to help you further research Technical Analysis, below are some other companies in the same sector:

BAX Technical Analysis
BDX Technical Analysis
BIIB Technical Analysis
BMY Technical Analysis
BSX Technical Analysis
CAH Technical Analysis
CELG Technical Analysis
CNC Technical Analysis
COO Technical Analysis
DGX Technical Analysis
More Healthcare companies »

 

AMGN Technical Analysis | www.TechnicalAnalysisChannel.com | Copyright © 2019 - 2021, All Rights Reserved

Nothing in TechnicalAnalysisChannel.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.